73.54
price up icon1.55%   1.12
after-market After Hours: 74.25 0.71 +0.97%
loading
Intra Cellular Therapies Inc stock is traded at $73.54, with a volume of 839.59K. It is up +1.55% in the last 24 hours and down -5.92% over the past month. Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$72.42
Open:
$74.89
24h Volume:
839.59K
Relative Volume:
0.85
Market Cap:
$7.77B
Revenue:
$563.44M
Net Income/Loss:
$-84.30M
P/E Ratio:
-45.68
EPS:
-1.61
Net Cash Flow:
$-61.23M
1W Performance:
+0.35%
1M Performance:
-5.92%
6M Performance:
+11.37%
1Y Performance:
+27.98%
1-Day Range:
Value
$73.02
$76.12
1-Week Range:
Value
$71.75
$76.12
52-Week Range:
Value
$45.50
$84.89

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name
Name
Intra Cellular Therapies Inc
Name
Phone
212-923-3344
Name
Address
430 EAST 29TH STREET, NEW YORK, NY
Name
Employee
561
Name
Twitter
Name
Next Earnings Date
2024-08-07
Name
Latest SEC Filings
Name
ITCI's Discussions on Twitter

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-03-24 Initiated Robert W. Baird Outperform
Dec-11-23 Initiated TD Cowen Outperform
Apr-20-23 Initiated Morgan Stanley Overweight
Aug-22-22 Downgrade Goldman Buy → Neutral
Jul-07-22 Initiated Mizuho Buy
Jun-14-22 Initiated UBS Buy
Apr-22-22 Initiated Piper Sandler Neutral
Feb-16-22 Initiated Goldman Buy
Sep-23-21 Initiated Needham Buy
Dec-15-20 Initiated BofA Securities Buy
Dec-10-20 Initiated Goldman Buy
Feb-20-20 Initiated Evercore ISI Outperform
Jan-31-20 Downgrade JP Morgan Overweight → Neutral
Dec-24-19 Reiterated Canaccord Genuity Buy
Aug-12-19 Initiated Jefferies Buy
Feb-26-18 Initiated JP Morgan Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Dec-15-17 Initiated Canaccord Genuity Buy
Nov-08-17 Upgrade SunTrust Hold → Buy
Sep-07-17 Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17 Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17 Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17 Downgrade Ladenburg Thalmann Buy → Neutral
May-02-17 Downgrade Leerink Partners Outperform → Mkt Perform
May-01-17 Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Sep-29-16 Reiterated RBC Capital Mkts Outperform
Sep-29-16 Downgrade SunTrust Buy → Neutral
View All

Intra Cellular Therapies Inc Stock (ITCI) Latest News

pulisher
Sep 06, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Lifted to Overweight at Piper Sandler - MarketBeat

Sep 06, 2024
pulisher
Sep 06, 2024

Expert Ratings For Intra-Cellular Therapies - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? - Yahoo Finance

Sep 06, 2024
pulisher
Sep 06, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $72.42 - MarketBeat

Sep 06, 2024
pulisher
Sep 05, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of New York Mellon Corp - MarketBeat

Sep 05, 2024
pulisher
Sep 05, 2024

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - MSN

Sep 05, 2024
pulisher
Sep 05, 2024

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey

Sep 05, 2024
pulisher
Sep 05, 2024

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Yahoo Finance

Sep 05, 2024
pulisher
Sep 04, 2024

How To Trade (ITCI) - Stock Traders Daily

Sep 04, 2024
pulisher
Sep 04, 2024

Peaking Back In On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha

Sep 04, 2024
pulisher
Sep 03, 2024

8,018 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Maryland State Retirement & Pension System - MarketBeat

Sep 03, 2024
pulisher
Sep 02, 2024

10 Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey

Sep 02, 2024
pulisher
Sep 02, 2024

Allspring Global Investments Holdings LLC Increases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Sep 02, 2024
pulisher
Sep 01, 2024

Privium Fund Management B.V. Has $8.09 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Sep 01, 2024
pulisher
Aug 31, 2024

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Breakeven? - Simply Wall St

Aug 31, 2024
pulisher
Aug 30, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 34,396 Shares - MarketBeat

Aug 30, 2024
pulisher
Aug 30, 2024

Intra-Cellular Therapies CEO sells over $5 million in company stock - Investing.com

Aug 30, 2024
pulisher
Aug 30, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat

Aug 30, 2024
pulisher
Aug 29, 2024

Intra-Cellular Therapies CEO sells over $7m in stock By Investing.com - Investing.com Australia

Aug 29, 2024
pulisher
Aug 29, 2024

Raymond James Trust N.A. Sells 194 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World

Aug 29, 2024
pulisher
Aug 28, 2024

Intra-Cellular Therapies CEO sells over $7m in stock - Investing.com

Aug 28, 2024
pulisher
Aug 28, 2024

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - Markets Insider

Aug 28, 2024
pulisher
Aug 28, 2024

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - GlobeNewswire

Aug 28, 2024
pulisher
Aug 28, 2024

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - Yahoo Finance

Aug 28, 2024
pulisher
Aug 28, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells $2,980,946.54 in Stock - MarketBeat

Aug 28, 2024
pulisher
Aug 27, 2024

Legato Capital Management LLC Purchases 9,923 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Aug 27, 2024
pulisher
Aug 26, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Calamos Advisors LLC - Defense World

Aug 26, 2024
pulisher
Aug 26, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Calamos Advisors LLC - MarketBeat

Aug 26, 2024
pulisher
Aug 25, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Nisa Investment Advisors LLC - Defense World

Aug 25, 2024
pulisher
Aug 24, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares of Stock - Defense World

Aug 24, 2024
pulisher
Aug 24, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 53,013 Shares of Stock - Defense World

Aug 24, 2024
pulisher
Aug 23, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares - MarketBeat

Aug 23, 2024
pulisher
Aug 23, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Envestnet Portfolio Solutions Inc. - Defense World

Aug 23, 2024
pulisher
Aug 22, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Given New $81.00 Price Target at JPMorgan Chase & Co. - Defense World

Aug 22, 2024
pulisher
Aug 21, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $81.00 at JPMorgan Chase & Co. - MarketBeat

Aug 21, 2024
pulisher
Aug 21, 2024

Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com Australia

Aug 21, 2024
pulisher
Aug 21, 2024

Weekly Research Analysts’ Ratings Changes for Intra-Cellular Therapies (ITCI) - Defense World

Aug 21, 2024
pulisher
Aug 21, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann Sells 18,714 Shares - Defense World

Aug 21, 2024
pulisher
Aug 21, 2024

Intra-Cellular Therapies executive sells over $1.4m in stock - Investing.com India

Aug 21, 2024
pulisher
Aug 20, 2024

Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com Canada

Aug 20, 2024
pulisher
Aug 20, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $1,405,047.12 in Stock - MarketBeat

Aug 20, 2024
pulisher
Aug 20, 2024

Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com UK

Aug 20, 2024
pulisher
Aug 19, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Cwm LLC - Defense World

Aug 19, 2024
pulisher
Aug 17, 2024

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation - Yahoo Finance

Aug 17, 2024
pulisher
Aug 17, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Decrease in Short Interest - Defense World

Aug 17, 2024
pulisher
Aug 17, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Decline in Short Interest - MarketBeat

Aug 17, 2024
pulisher
Aug 17, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 17, 2024
pulisher
Aug 17, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

Assenagon Asset Management S.A. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

Oak Ridge Investments LLC Invests $811,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Aug 15, 2024
pulisher
Aug 14, 2024

Financial Review: Prelude Therapeutics (NASDAQ:PRLD) and Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World

Aug 14, 2024

Intra Cellular Therapies Inc Stock (ITCI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Intra Cellular Therapies Inc Stock (ITCI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mates Sharon
Chairman and CEO
Aug 29 '24
Option Exercise
12.73
35,604
453,239
1,105,933
Mates Sharon
Chairman and CEO
Aug 30 '24
Option Exercise
12.73
34,396
437,861
1,104,725
Mates Sharon
Chairman and CEO
Aug 29 '24
Sale
72.57
35,604
2,583,884
1,070,329
Mates Sharon
Chairman and CEO
Aug 30 '24
Sale
72.84
34,396
2,505,351
1,070,329
$15.09
price down icon 1.69%
$60.01
price down icon 0.65%
$120.17
price down icon 0.86%
drug_manufacturers_specialty_generic RDY
$79.20
price down icon 0.55%
$11.27
price down icon 3.43%
Cap:     |  Volume (24h):